MA54143A - Compositions et méthodes - Google Patents

Compositions et méthodes

Info

Publication number
MA54143A
MA54143A MA054143A MA54143A MA54143A MA 54143 A MA54143 A MA 54143A MA 054143 A MA054143 A MA 054143A MA 54143 A MA54143 A MA 54143A MA 54143 A MA54143 A MA 54143A
Authority
MA
Morocco
Prior art keywords
compositions
methods
Prior art date
Application number
MA054143A
Other languages
English (en)
Inventor
Sarah C Gilbert
Adrian V S Hill
Teresa Lambe
Sarah Sebastian
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MA54143A publication Critical patent/MA54143A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA054143A 2018-11-06 2019-11-05 Compositions et méthodes MA54143A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1818084.4A GB201818084D0 (en) 2018-11-06 2018-11-06 Compositions and methods

Publications (1)

Publication Number Publication Date
MA54143A true MA54143A (fr) 2022-02-16

Family

ID=64655509

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054143A MA54143A (fr) 2018-11-06 2019-11-05 Compositions et méthodes

Country Status (12)

Country Link
US (1) US20220001007A1 (fr)
EP (1) EP3876984A1 (fr)
JP (2) JP7579245B2 (fr)
KR (1) KR20210090208A (fr)
CN (1) CN113226364A (fr)
AU (1) AU2019374480A1 (fr)
CA (1) CA3118641A1 (fr)
GB (1) GB201818084D0 (fr)
MA (1) MA54143A (fr)
MX (1) MX2021005345A (fr)
SG (1) SG11202104448WA (fr)
WO (1) WO2020095038A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023056912A1 (fr) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Vaccins à base d'acide nucléique pour vzv
CN114081943B (zh) * 2021-11-08 2024-04-02 中国医学科学院医学生物学研究所 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用
CN114163503B (zh) * 2021-12-15 2023-11-24 北京交通大学 两种表达水痘-带状疱疹病毒的gE蛋白的重组腺病毒及应用
CN114703205A (zh) * 2022-03-11 2022-07-05 上海博唯生物科技有限公司 一种疱疹病毒糖蛋白gE重组蛋白、疫苗、制备方法和应用
WO2023240196A1 (fr) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions et leurs méthodes d'utilisation
CN116474086A (zh) * 2022-11-24 2023-07-25 中国药科大学 一种预防和/或治疗带状疱疹病的疫苗试剂
WO2024156053A1 (fr) * 2023-01-24 2024-08-02 Providence Therapeutics Holdings Inc. Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv)
CN118374514A (zh) * 2024-06-26 2024-07-23 成都康华生物制品股份有限公司 一种带状疱疹mRNA及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721981A4 (fr) * 2004-03-05 2007-03-14 Univ Osaka Res Found Virus recombine de la varicelle et du zona
CA2587084C (fr) * 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation de la valeur adaptative reproductive au moyen de codons synonymes employes moins frequemment
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
EP2175882A4 (fr) 2007-07-19 2011-11-30 Novavax Inc Particules de type virus (vlp) du virus de la varicelle et du zona et antigènes
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
EP3833382A1 (fr) * 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processus et vaccins
CN113164586B (zh) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 免疫组合物及其制备方法与应用

Also Published As

Publication number Publication date
JP7579245B2 (ja) 2024-11-07
MX2021005345A (es) 2021-09-10
JP2022506410A (ja) 2022-01-17
WO2020095038A1 (fr) 2020-05-14
GB201818084D0 (en) 2018-12-19
CN113226364A (zh) 2021-08-06
KR20210090208A (ko) 2021-07-19
CA3118641A1 (fr) 2020-05-14
AU2019374480A1 (en) 2021-05-27
JP2024133649A (ja) 2024-10-02
SG11202104448WA (en) 2021-05-28
EP3876984A1 (fr) 2021-09-15
US20220001007A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
EP3600325A4 (fr) Nouvelles compositions et méthodes
EP3694869A4 (fr) Méthodes et compositions de sélection transgénique
EP3843739A4 (fr) Nouvelles méthodes
EP3436083A4 (fr) Nouvelles compositions et méthodes
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
EP3843738A4 (fr) Nouvelles méthodes
DK3478811T3 (da) Rengøringssammensætninger og anvendelser deraf
EP3801527A4 (fr) Nouvelles méthodes
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
MA54143A (fr) Compositions et méthodes
EP3324978A4 (fr) Compositions d'oligonucléotides et méthodes associées
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
EP3845532A4 (fr) Dérivé de quinolino-pyrrolidin-2-one et application associée
EP3790861A4 (fr) Compositions sénolytiques et utilisations associées
EP3273950A4 (fr) Compositions adjuvantes et méthodes associées
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
EP3741810A4 (fr) Composition de silicone
PL3293188T3 (pl) Silany i utwardzalne kompozycje obejmujące wskazane silany
EP3630150A4 (fr) Compositions anthelminthiques purifiées et méthodes associées
EP3688069A4 (fr) Compositions de silicone
EP3436467A4 (fr) Nouvelles compositions et méthodes thérapeutiques
EP3380471A4 (fr) Méthodes et compositions d'inhibition de comt
EP3893901A4 (fr) Compositions et méthodes pour immunothérapies